D
Dolores Diaz
Researcher at Genentech
Publications - 43
Citations - 3071
Dolores Diaz is an academic researcher from Genentech. The author has contributed to research in topics: Glutathione & Mucopolysaccharidosis type II. The author has an hindex of 20, co-authored 43 publications receiving 2640 citations. Previous affiliations of Dolores Diaz include University of Washington & Fred Hutchinson Cancer Research Center.
Papers
More filters
Journal ArticleDOI
High concordance of drug-induced human hepatotoxicity with in vitro cytotoxicity measured in a novel cell-based model using high content screening.
Peter J. O'Brien,William Irwin,Dolores Diaz,E. Howard-Cofield,C. M. Krejsa,M. R. Slaughter,B. Gao,Nina Kaludercic,A. Angeline,Paolo Bernardi,P. Brain,C. Hougham +11 more
TL;DR: It is concluded that human hepatotoxicity is highly concordant with in vitro cytotoxicity in this novel model and as detected by HCS.
Journal ArticleDOI
Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapy
Joel D. Leverson,Darren C. Phillips,Michael J. Mitten,Erwin R. Boghaert,Dolores Diaz,Stephen K. Tahir,Lisa D. Belmont,Paul Nimmer,Yu Xiao,Xiaoju Max Ma,Kym N Lowes,Kym N Lowes,Peter Kovar,Jun Chen,Sha Jin,Morey L. Smith,John Xue,Haichao Zhang,Anatol Oleksijew,Terrance J. Magoc,Kedar S. Vaidya,Daniel H. Albert,Jacqueline M. Tarrant,Nghi La,Le Wang,Zhi-Fu Tao,Michael D. Wendt,Deepak Sampath,Saul H. Rosenberg,Chris Tse,David C.S. Huang,David C.S. Huang,Wayne J. Fairbrother,Steven W. Elmore,Andrew J. Souers +34 more
TL;DR: BCL-XL–selective inhibitors have the potential to enhance the efficacy of docetaxel in solid tumors and avoid the exacerbation of neutropenia observed with navitoclax, and demonstrate the translational utility of this toolkit of selective BCL-2 family inhibitors.
Journal ArticleDOI
Glutathione redox potential in response to differentiation and enzyme inducers
TL;DR: Redox changes in response to physiologic stimuli such as differentiation and enzyme inducers are of a sufficient magnitude to control the activity of redox-sensitive proteins, suggesting that physiologic modulation of the 2GSH/GSSG redox poise could provide a fundamental parameter for the control of cell phenotype.
Journal ArticleDOI
A Novel Tankyrase Small-Molecule Inhibitor Suppresses APC Mutation–Driven Colorectal Tumor Growth
Ted Lau,Emily Chan,Marinella Callow,Jo Waaler,Jason Boggs,Robert A. Blake,Steven Magnuson,Amy Sambrone,Melissa Schutten,Ron Firestein,Ondrej Machon,Vladimir Korinek,Edna F. Choo,Dolores Diaz,Mark Merchant,Paul Polakis,Daniel D. Holsworth,Stefan Krauss,Mike Costa +18 more
TL;DR: A potent and specific small-molecule tankyrase inhibitors are developed that reduce Wnt/β-catenin signaling by preventing poly(ADP-ribosyl)ation-dependent AXIN degradation, thereby promoting β- catenin destabilization and establishing proof-of-concept antitumor efficacy for tankyrases in APC-mutant CRC models.
Journal ArticleDOI
Applications of cytotoxicity assays and pre-lethal mechanistic assays for assessment of human hepatotoxicity potential.
TL;DR: Since inter-individual therapeutic index (TI) may differ from patient to patient, the rational use of one or more of these cellular assay and targeted in vivo exposure data may allow pharmaceutical scientists to select drug candidates with a higher TI potential in the drug discovery phase.